Login
Home / CHMP : OTC
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Champion Industries Inc

$0.02 +$0.00 (+0.00%)
OTC · 14 Sep 2026 20:00 UTC
Previous Close
$0.02
Day Range
$0$0.02
Year Range
$0$0.02
Market Cap
1.13K
AVG Volume
43
Trailing/Forward PE
-0/-
PEG ratio
0
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (USD)
05M10M15M20M14 Q314 Q415 Q115 Q215 Q315 Q416 Q116 Q216 Q316 Q4
Net Income (USD)
-750K-500K-250K0250K500K14 Q314 Q415 Q115 Q215 Q315 Q416 Q116 Q216 Q316 Q4
Operating Income (USD)
-500K-250K0250K500K750K14 Q314 Q415 Q115 Q215 Q315 Q416 Q116 Q216 Q316 Q4
EBITDA (USD)
0500K1M1.5M14 Q314 Q415 Q115 Q215 Q315 Q416 Q116 Q216 Q316 Q4
Cash Flows (USD)
-1M-500K0500K1M14 Q314 Q415 Q115 Q215 Q315 Q416 Q116 Q216 Q316 Q4
EPS (USD)
-15-10-5051014 Q314 Q415 Q115 Q215 Q315 Q416 Q116 Q216 Q316 Q4
Expenses (USD)
02M4M6MSG&ACapex14 Q314 Q415 Q115 Q215 Q315 Q416 Q116 Q216 Q316 Q4
Cash & Debt (USD)
05M10M15MCashLong Term DebtShort Term Debt14 Q314 Q415 Q115 Q215 Q315 Q416 Q116 Q216 Q316 Q4
Debt ratios
02.557.51014 Q314 Q415 Q115 Q215 Q315 Q416 Q116 Q216 Q316 Q4
Margins
0%10%20%30%14 Q314 Q415 Q115 Q215 Q315 Q416 Q116 Q216 Q316 Q4
Return on Capital
-40%-20%0%20%14 Q314 Q415 Q115 Q215 Q315 Q416 Q116 Q216 Q316 Q4
Shares Outstanding
020K40K60K14 Q314 Q415 Q115 Q215 Q315 Q416 Q116 Q216 Q316 Q4
Dividends (USD)
051015Aug 06Dec 06Mar 07Jun 07Aug 07Dec 07Mar 08Jun 08Aug 08Dec 08
Book Value Per Share (USD)
020406014 Q314 Q415 Q115 Q215 Q315 Q416 Q116 Q216 Q316 Q4
Total Assets (USD)
010M20M30M14 Q314 Q415 Q115 Q215 Q315 Q416 Q116 Q216 Q316 Q4
PE Ratio
010203040med 0.92Jun 11Oct 11Jan 12May 14Aug 14Nov 14Mar 15
Free Cash Flow Yield
0%5000000%10000000%15000000%med 12992854.94%Jan 25May 25Sep 25Jan 26May 26Sep 26
Price to Sales
00000med 0Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
EV/EBITDA
9.439.439.439.43med 9.43Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Price/Operating Cashflow
00000med 0Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Price to Book
00000med 0Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Champion Industries Inc
CHMP
Stockpicker

Video analysis: CHMP

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: CHMP

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

gurufocus.com · 6 Aug 2026

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular d
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

gurufocus.com · 29 Jun 2026

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

gurufocus.com · 26 Jun 2026

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positi
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

gurufocus.com · 26 Jun 2026

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) acro
Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.